Group 1 - The A-share market saw a significant decline in innovative drug concept stocks, with notable drops including Aidi Pharmaceutical down over 11% and Yifang Bio down over 5% [1] - Other companies such as Xingqi Pharmaceutical, Zhenbaodao, and Dize Pharmaceutical experienced declines of over 4%, while Rongchang Bio, Hanshang Group, Yuekang Pharmaceutical, Xinlitai, Haishike, Shanghai Yizhong, and Kanghong Pharmaceutical fell by over 3% [1] Group 2 - Aidi Pharmaceutical (688488) reported a decline of 11.33%, with a total market value of 7.835 billion and a year-to-date increase of 14.02% [2] - Yifang Bio (688382) decreased by 5.99%, with a market capitalization of 15 billion and a year-to-date decline of 4.99% [2] - Xingqi Pharmaceutical (300573) fell by 4.82%, with a market value of 19.4 billion and a year-to-date increase of 12.01% [2] - Zhenbaodao (603567) dropped by 4.74%, with a market capitalization of 7.951 billion and a year-to-date decline of 5.38% [2] - Dize Pharmaceutical (688192) decreased by 4.19%, with a market value of 27.5 billion and a year-to-date increase of 2.78% [2] - Rongchang Bio (688331) fell by 3.98%, with a market capitalization of 56.1 billion and a year-to-date increase of 27.79% [2] - Hanshang Group (600774) decreased by 3.93%, with a market value of 3.101 billion and a year-to-date increase of 14.99% [2] - Yuekang Pharmaceutical (688658) dropped by 3.84%, with a market capitalization of 12 billion and a year-to-date increase of 18.40% [2] - Xinlitai (002294) fell by 3.32%, with a market value of 55.5 billion and a year-to-date increase of 0.48% [2] - Haishike (002653) decreased by 3.23%, with a market capitalization of 56.1 billion and a year-to-date decline of 2.44% [2] - Shanghai Yizhong (688091) dropped by 3.17%, with a market value of 11.2 billion and a year-to-date increase of 15.60% [2] - Kanghong Pharmaceutical (002773) fell by 3.15%, with a market capitalization of 29.5 billion and a year-to-date increase of 6.81% [2]

本报记者 曹卫新 开年以来，上市公司并购重组积极性持续升温。在政策引导与资本加持的双重作用下，市场资源正加速 向战略性新兴产业集中。据Wind资讯数据统计，按首次披露日期计，1月1日至21日，A股市场累计披露 240起并购重组事件。其中，10单涉及重大资产重组。 据和利时电机官网信息，该公司成立于1995年，20余年来一直专注于电机、驱动器及控制系统的研发， 靠过硬的产品品质及给用户的优质服务和技术支持赢得了用户的口碑及信赖。公司自主研制的步进电机 及驱动器、交流伺服电机及驱动器、无刷直流电机及驱动器三大系列核心产品（100余种驱动器，近500 种电机）已经占据国内市场的相当份额，销售收入每年平均增长率达到20%。 除高端制造领域外，医药行业的并购重组也较为活跃。例如，1月14日，江苏艾迪药业集团股份有限公 司发布公告称，公司拟向不超过35名特定投资者发行股份募集资金总额不超过1.85亿元，用于收购南京 南大药业有限责任公司（以下简称"南大药业"）22.23%股权及补充流动资金。收购完成后，公司对南大 药业的直接持股比例将由51.13%增加至73.36%。 深度科技研究院院长张孝荣对《证券日报》记者表示，战略 ...

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

（文章来源：北京商报） 公告显示，多替拉韦拉米夫定替诺福韦片是由公司开发的用于治疗HIV-1感染的化学药品2.3类复方制 剂。 北京商报讯1月19日晚间，艾迪药业（688488）发布公告称，公司收到国家药品监督管理局于1月18日核 准签发的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研2.3类改良型新药多替拉韦拉米夫 定替诺福韦片（ADC205片）开展临床试验。 ...

Core Insights - Yangzhou is recognized as a city of canals, cuisine, and culture, showcasing its historical and commercial value through the World Canal Historical and Cultural Cities Cooperation Organization (WCCO) and its media platform, Dayunhe Media [1] - The latest Hurun Rich List highlights the top ten wealth creators in Yangzhou for 2025, emphasizing the entrepreneurial spirit and innovative capabilities of local business leaders [1] Group 1: Top Wealth Creators - The richest individual is Liang Qin, Chairman of Yangjie Electronics Technology, with a net worth of 16 billion yuan, ranking 411th nationally. The company has evolved from a trading firm to a leading IDM model enterprise in power semiconductors [1] - Zhu Daqing, Chairman of Tianfulong Group, ranks second with a net worth of 13 billion yuan, marking his debut on the Hurun Rich List. The company is a leader in differentiated polyester short fibers, focusing on "technology innovation + green transformation" [3] - Zhu Yinghui, holding 36.17% of Rongtai Co., ranks third with a net worth of 5.5 billion yuan. The company specializes in precision die-casting for automotive lightweight components [4] - Zhou Guangrong, Chairman of Haichang New Materials, has a combined net worth of approximately 5.3 billion yuan with his wife. The company is a leader in the powder metallurgy industry, particularly in electric tool components [6] - Li Hongqing, former actual controller of Jiangsu Aoliwei Sensor, has a net worth of at least 3.8 billion yuan, focusing on automotive parts and sensors [8] - Fu Helian, Chairman of Aidi Pharmaceutical Group, has a net worth of 3.8 billion yuan, leading a company that specializes in innovative drugs for major diseases [10] - Zou Weimin, Chairman of Chuan Yi Technology, has a net worth of approximately 3.1 billion yuan, focusing on computer keyboards and control panels [12] - Zhang Wensheng, Chairman of Beijiajie Group, has a net worth of about 2.4 billion yuan, specializing in oral care and hygiene products [13] - Zhu Xingrong, General Manager of Tianfulong Group, is the youngest on the list at 2.3 billion yuan, holding 13.14% of the company's shares [15] - Lin Mingwen, Chairman of Yangzhou Jinqian Tourism Products, has a net worth of approximately 1.5 billion yuan, focusing on outdoor products [16] Group 2: Entrepreneurial Insights - Over half of the top ten wealth creators started from grassroots sales or technical positions, demonstrating their ability to seize opportunities during industry transformations [16]

证券代码：688488 证券简称：艾迪药业 公告编号：2026-011 江苏艾迪药业集团股份有限公司 关于 ADC205 片获得药物临床试验批准通知书的 自愿性披露公告 一、通知书基本情况 药品名称：多替拉韦拉米夫定替诺福韦片 受理号：CXHL2501238 申请事项：境内生产药品注册临床试验 申请人：江苏艾迪药业集团股份有限公司 通知书编号：2026LP00163 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 11 月 11 日受理的多替拉韦拉米夫定替诺福韦片临床试验申请符合药品注册的 有关要求，同意本品开展作为一个完整的治疗方案适用于治疗患有人类免疫缺陷 病毒 1 型（HIV-1）感染的成人和体重 35kg 或以上的儿童患者的临床试验。 二、药品相关情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏艾迪药业集团股份有限公司（以下简称"公司"）收到国家药品监督管 理局（以下简称"国家药监局"）于 2026 年 1 月 18 日核准签发的《药物临床试 验批准通知书》（以下简称"通知书" ...

本品组方内的3种有效成分均已作为单药上市并用于艾滋病治疗多年，作用机制明确。目前，以拉米夫 定（3TC）、富马酸替诺福韦二吡呋酯（TDF）为骨干，多替拉韦（DTG）为核心的抗逆转录病毒治疗 方案（ART）具有抗病毒疗效高、抑制病毒速度快等优点，世界卫生组织指南（2021）、欧洲艾滋病临 床协会指南（2024）、美国卫生及公共服务部指南（2024）、美国国际抗病毒协会指南（2024）以及 《中国艾滋病诊疗指南（2024版）》等国内外权威指南均将该三药联用方案列为HIV人群的推荐治疗方 案之一。 多替拉韦拉米夫定替诺福韦片（以下简称"本品"）是由公司开发的用于治疗HIV-1感染的化学药品2.3类 复方制剂，其组份为：每片含多替拉韦钠（按C20H19F2N3O5计）50mg，拉米夫定300mg，富马酸替诺 福韦二吡呋酯300mg，拟作为一个完整的治疗方案适用于治疗患有人类免疫缺陷病毒1型（HIV-1）感染 的成人和体重35kg或以上的儿童患者。 格隆汇1月19日丨艾迪药业(688488.SH)公布，公司收到国家药品监督管理局于2026年1月18日核准签发 的《药物临床试验批准通知书》，同意公司抗艾滋病领域在研2.3 ...

每经AI快讯，1月19日，艾迪药业公告称，公司收到国家药品监督管理局核准签发的《药物临床试验批 准通知书》，同意公司抗艾滋病领域在研2.3类改良型新药多替拉韦拉米夫定替诺福韦片(ADC205片)开 展临床试验。 ...

| 代码 | 简称 | 最新融资余额（万 | 较前一个交易日增减 | 当日涨跌幅（%） | 所属行业 | | --- | --- | --- | --- | --- | --- | | | | 元） | （%） | | | | 688488 | 艾迪药 业 | 27783.57 | 74.10 | 2.96 | 医药生物 | | 601799 | 星宇股 份 | 29085.74 | 49.50 | -1.15 | 汽车 | | 920580 | 科创新 材 | 872.49 | 43.70 | 5.42 | 建筑材料 | | 301266 | 宇邦新 材 | 18848.82 | 43.38 | 17.20 | 电力设备 | | 600744 | 华银电 力 | 24596.97 | 42.75 | 7.98 | 公用事业 | | 002707 | 众信旅 游 | 53240.43 | 42.12 | -8.47 | 社会服务 | | 688548 | 广钢气 体 | 27349.12 | 38.29 | 10.50 | 电子 | | 301021 | 英诺激 光 | 34100.29 | 37.36 | ...

Core Viewpoint - Eddy Pharmaceutical (688488) has seen a significant stock price increase of 22.17% this week, closing at 21.6 yuan, with a market capitalization of 9.089 billion yuan as of January 16, 2026 [1] Trading Information Summary - Eddy Pharmaceutical reached a maximum price of 22.11 yuan on January 16, 2026, marking a near one-year high, and was listed on the Shanghai and Shenzhen Stock Exchanges' "Dragon and Tiger List" due to a price increase of 15% on January 14, 2026 [1][4] - The company’s Vice President Wang Guangrong, Yu Ke, and non-independent director Liu Yan faced regulatory measures from the Shanghai Stock Exchange for information disclosure violations [1][4] Company Announcement Summary - On January 13, 2026, Eddy Pharmaceutical's board approved a plan to issue A-shares to specific investors, aiming to raise no more than 185 million yuan for acquiring a 22.2324% stake in Nanjing Nanda Pharmaceutical and for supplementing working capital [1][4] - The company plans to acquire the minority stake in Nanjing Nanda Pharmaceutical for 130.05954 million yuan, increasing its ownership from 51.1256% to 73.3580% [2][4] - The board also decided to terminate the previous plan for a 2024 A-share issuance to specific investors [1][5] Fundraising and Financial Strategy - The total amount to be raised from the new issuance is capped at 185 million yuan, with 130 million yuan allocated for the acquisition and 55 million yuan for working capital [3][6] - The company has outlined a three-year shareholder dividend plan, committing to distribute at least 10% of the annual distributable profits in cash, with a cumulative cash dividend of no less than 30% of the average distributable profits over the past three years [2]